Business
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
GAITHERSBURG, Md., March 11, 2026--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
About this update from Genedx Holdings Corp.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":232,"url":"https://media.zenfs.com/en/business-wire.com/ff86f7f153272dcbb6c1f2204d21979f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3m8SHg_qbiyd4jiweEoMwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ2NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ff86f7f153272dcbb6c1f2204d21979f","width":480,"height":232},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/XtdgiYkeUiT1k8weJoLE3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMwOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ff86f7f153272dcbb6c1f2204d21979f","width":480,"height":232}},"lazy":false},{"type":"text","content":"New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result","length":190,"tagName":"p","attribs":{}},{"type":"text","content":"GAITHERSBURG, Md., March 11, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact of whole exome sequencing (WES) and whole genome sequencing (WGS) in children with neurodevelopmental disorders, like epilepsy and developmental delay and intellectual disability (DD/ID). The data was unveiled today at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting in Baltimore, MD.","length":714,"tagName":"p"},{"type":"text","content":"The study demonstrates that GeneDx’s ExomeDx™ and GenomeDx™ significantly reduce total healthcare costs in the 12- and 24-months following testing for patients covered by private insurance and Medicaid.","length":202,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Savings were primarily driven by fewer hospitalizations and reduced emergency room utilization – patterns consistent with accurate diagnoses and more targeted, high-value care after genomic testing.","length":198,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additionally, the study found that ...